ANI Pharmaceuticals (ANIP) FY2016 results: revenue $129 million, up 68.5% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $129 million for fiscal 2016, the year ended 31 December 2016, up 68.5% on the year before. Net income was $4 million, down 74.4%, and diluted earnings per share $0.34. The figures are the company's own, from the 10-K it filed with the SEC on 2 March 2017.
Revenue
$129 million
+68.5% on the year
FY2009FY2016
Operating margin
15.6%
42.8% a year earlier
FY2009FY2016
Net income
$4 million
-74.4% on the year
FY2009FY2016
Diluted EPS
$0.34
-74.2% on the year
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
129
76.3
56.0
+68.5%
Cost of revenue
48.8
12.7
11.5
+284.3%
Gross profit
79.8
63.6
44.5
+25.5%
Gross margin
62.1%
83.4%
79.5%
Research and development
2.9
2.9
2.7
+1.1%
Selling, general and administrative
27.8
21.2
17.9
+31.5%
Operating income
20.1
32.7
20.0
-38.6%
Operating margin
15.6%
42.8%
35.7%
Interest expense
11.3
11.1
0.8
+1.4%
Pre-tax income
8.7
21.7
19.4
-60.1%
Income tax
4.7
6.4
-9.4
-25.4%
Effective tax rate
54.7%
29.3%
-48.3%
Net income
3.9
15.4
28.7
-74.4%
Net margin
3.1%
20.1%
51.4%
Diluted EPS
$0.34
$1.32
$2.59
-74.2%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
27.5
17.3
22.0
+59.1%
Capital expenditure
4.6
2.2
1.1
+109.2%
Free cash flow
22.9
15.1
20.9
+51.9%
Free cash flow margin
17.8%
19.8%
37.4%
Cash from investing
-149
-32.7
-35.8
Cash from financing
-0.7
1.1
172
Depreciation and amortisation
22.3
6.9
3.9
+223.8%
Share-based compensation
6.1
3.9
3.4
+57.3%
Buybacks
2.5
0.0
0.0
Diluted shares, weighted
12m
12m
11m
+0.1%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
170
160
140
+6.0%
Debt
121
113
107
+6.4%
Other liabilities
32.6
11.8
13.2
+177.1%
Total liabilities and equity
323
285
260
+13.2%
Fixed assets
11.0
7.1
5.2
+54.2%
Goodwill
1.8
1.8
1.8
0.0%
Intangible assets
176
66.4
42.1
+164.8%
Cash and equivalents
27.4
155
169
-82.3%
Receivables
45.9
21.9
17.3
+109.3%
Inventory
26.2
13.4
7.5
+95.6%
Other assets
34.8
19.9
16.6
+74.9%
Total assets
323
285
260
+13.2%
10-K for the year ended 31 December 2016, filed 2 March 2017: the filing.